Discussion {#onco12957-sec-0006}
==========

GCTB are rare, locally aggressive bone tumors with the capacity to metastasize. The mainstay of treatment is surgical resection, either en bloc resection or curettage with or without local adjuvants like phenol, liquid nitrogen, or polymethylmethacrylate (PMMA). The majority of recurrences after primary intralesional surgery are seen in so‐called high‐risk GCTB. This group includes tumors with extension into surrounding soft tissue, (intra‐articular) pathologic fracture, recurrences, absence of local adjuvant therapy after primary curettage, and localization in the spine or sacrum. A systemic adjuvant treatment may be beneficial for this category of patients. Zoledronic acid has shown in different in vitro and animal studies to induce GCTB neoplastic stromal cell inhibition, apoptosis, and osteogenic differentiation. Further case reports and series support the beneficial use of zoledronic acid and other bisphosphonates as (neo)adjuvant or definitive treatment of GCTB.

We performed a multicenter randomized open‐label phase II trial in patients with high‐risk GCTB. The primary objective was to determine the 2‐year recurrence rate of GCTB after adjuvant zoledronic acid versus standard care. The trial\'s low accrual and early closure were due to the clinical introduction of denosumab in the treatment of GCTB.

Zoledronate did not decrease the recurrence rate of GCTB in this study. Although this was a randomized study, the (nonsignificant) higher number of recurrences in the zoledronate arm may be explained by more patients with a recurrent GCTB and soft tissue involvement, as well as more patients who had received suboptimal primary treatment with curettage instead of en bloc resection at primary surgery. All four patients who had a recurrence were treated with curettage, one without local adjuvants. Recurrence rates for the high‐risk cases described here are comparable to average recurrence rates in our previously published report. All recurrences were seen within the first 2 years after surgery, which is comparable to the literature.

Two other prospective trials were performed on the effects of adjuvant treatment with bisphosphonates in GCTB. These small nonrandomized trials with different bisphosphonates resulted in recurrence rates of 0%--15% after a follow‐up of 25--58 months.

The position of zoledronic acid in the treatment of GCTB next to denosumab is undetermined. Its use in advanced GCTB has strongly increased over the past few years because of several larger clinical trials that demonstrated tumor growth inhibition and reduced surgical morbidity. Despite these positive outcomes, doubts are also raised regarding the risk of tumor recurrence after denosumab withdrawal. It is suggested that a complete pathological response cannot be achieved, because denosumab does not have an apoptotic effect on the neoplastic stromal cell population. Therefore, zoledronic acid might be a more suitable (neo)adjuvant treatment option. Larger randomized trials with zoledronic acid are needed to give us further insight to the optimal treatment strategy in advanced GCTB.

Trial Information {#onco12957-sec-0007}
=================

**Disease**Giant cell tumor of bone**Stage of Disease/Treatment**Adjuvant**Prior Therapy**None**Type of Study ‐ 1**Phase II**Type of Study ‐ 2**Randomized**Primary Endpoint**2‐year recurrence rate**Secondary Endpoint**Relapse‐free survival**Additional Details of Endpoints or Study Design** This study was designed as a randomized, open‐label, multicenter phase II trial. Patients were eligible if they had a high‐risk GCTB treated with surgery. The primary objective was to determine the 2‐year recurrence rate of high‐risk GCTB after adjuvant zoledronic acid compared with standard care in the control arm. High‐risk GCTB was defined as one or more of the following: localization in pelvis, spine, sacrum, or distal ulna; joint or soft tissue involvement; pathologic fracture; grade III; or absence of local adjuvant therapy or recurrent GCTB. Patients with metastases, malignant GCTB, or prior use of bisphosphonates were excluded. Statistical methods: In case 90 patients were randomized in the study (45 in each arm), the study would have 95% power (α = .1; P0 = 45%, one‐tailed test) to detect differences between the recurrence rate in the two arms of 30% and 85% power to detect a difference of 25%. Relapse‐free survival curves were calculated by means of the using Kaplan‐Meier technique. The target number of patients was not reached because of low accrual after the introduction of denosumab in this patient group. Given the low accrual numbers, Fisher\'s exact test was used to assess differences between the treatment groups. **Investigator\'s Analysis**Active, but patient numbers too low for accurate comparison.

Drug Information: Zoledronic Acid Arm {#onco12957-sec-0008}
=====================================

Drug 1  **Generic/Working Name**Zoledronic acid **Drug Type**Small molecule **Dose**4 milligrams (mg) per flat dose **Route**IV **Schedule of Administration**Monthly for 3 months followed by a 3‐monthly schedule for up to 1 year after surgery. All subjects received daily supplements of 500 mg calcium and 400 IU of vitamin D, unless documented hypercalcemia (albumin‐adjusted serum calcium \>2.9 mmol/L \[11.5 mg/dL\] or ionized calcium \>1.5 mmol/L) developed on study.

Patient Characteristics: Zoledronic Acid Arm {#onco12957-sec-0009}
============================================

Number of Patients, Male4Number of Patients, Female4StageHigh‐risk GCTBAgeMedian (range): 34 (21--55) yearsPerformance Status: ECOG0 --- 31 --- 52 ---3 ---Unknown ---OtherComplete baseline demographic and disease characteristics are presented in Table [1](#onco12957-tbl-0001){ref-type="table"}.

###### Local recurrences after adjuvant systemic therapy with zoledronic acid compared with standard care, including known risk factors for recurrence

![](onco12957-tbl-0001){#nlm-graphic-1}

Abbreviation: GCTB, giant cell tumor of bone.

Patient Characteristics: Control Arm {#onco12957-sec-0010}
====================================

Number of Patients, Male4Number of Patients, Female2StageHigh‐risk GCTBAgeMedian (range): 45.5 (19--73) yearsPerformance Status: ECOG0 --- 21 --- 42 ---3 ---Unknown ---OtherComplete baseline demographic and disease characteristics are presented in Table [1](#onco12957-tbl-0001){ref-type="table"}.

Primary Assessment Method: Control Arm {#onco12957-sec-0011}
======================================

Title2‐year recurrence rateNumber of Patients Enrolled7Number of Patients Evaluable for Toxicity6Number of Patients Evaluated for Efficacy6Evaluation MethodOther (recurrence confirmed by imaging and histology)Outcome NotesControl Arm: Response Assessment: 2‐year recurrence rate, 17% (*n* = 1); time to recurrence, median, 6 months.

Primary Assessment Method: Zoledronic Acid Arm {#onco12957-sec-0012}
==============================================

Title2‐year recurrence rateNumber of Patients Enrolled8Number of Patients Evaluable for Toxicity8Number of Patients Evaluated for Efficacy8Evaluation MethodOther (recurrence confirmed by imaging and histology)Outcome NotesZoledronic acid Arm: Response Assessment: 2‐year recurrence rate, 38% (*n* = 3); time to recurrence, median (range), 5 months (4--15 months).

Adverse Events {#onco12957-sec-1012}
==============

imageJohn Wiley & Sons, Ltd.[^1][^2]

Assessment, Analysis, and Discussion {#onco12957-sec-0013}
====================================

CompletionStudy terminated before completionTerminated ReasonCompeting agentsInvestigator\'s AssessmentActive, but patient numbers too low for accurate comparison.

 {#onco12957-sec-1013}

Giant cell tumors of bone (GCTBs) are rare, locally aggressive bone tumors with capacity to metastasize \[[1](#onco12957-bib-0001){ref-type="ref"}\]. Their occurrence is most frequent in patients aged 30--40 years, in the metaphysis of long bones, but the tumors can also be found in other bones \[[2](#onco12957-bib-0002){ref-type="ref"}\]. Histologically, GCTB consists of reactive osteoclast‐like giant cells expressing receptor activator of nuclear factor kappa‐B (RANK) with a CD33+CD14− phenotype \[[3](#onco12957-bib-0003){ref-type="ref"}\], mononuclear osteoclast precursor cells, and neoplastic spindle‐shaped cells expressing RANK‐ligand \[[4](#onco12957-bib-0004){ref-type="ref"}\]. RANK signaling promotes the generation of multinuclear osteoclast, which results in bone resorption among others by the production of the principal protease cathepsin K \[[5](#onco12957-bib-0005){ref-type="ref"}\], \[[6](#onco12957-bib-0006){ref-type="ref"}\], \[[7](#onco12957-bib-0007){ref-type="ref"}\].

The mainstay of treatment is surgical resection, either en bloc resection or curettage with or without local adjuvants like phenol, liquid nitrogen, or polymethylmethacrylate (PMMA) \[[8](#onco12957-bib-0008){ref-type="ref"}\], \[[9](#onco12957-bib-0009){ref-type="ref"}\], \[[10](#onco12957-bib-0010){ref-type="ref"}\], \[[11](#onco12957-bib-0011){ref-type="ref"}\], \[[12](#onco12957-bib-0012){ref-type="ref"}\]. The majority of recurrences after primary intralesional surgery are seen in so‐called high‐risk GCTB. This group includes tumors with extension into surrounding soft tissue, (intra‐articular) pathologic fracture, recurrences, absence of local adjuvant therapy after primary curettage, and localization in the spine or sacrum \[[13](#onco12957-bib-0013){ref-type="ref"}\], \[[14](#onco12957-bib-0014){ref-type="ref"}\]. A systemic adjuvant treatment may be beneficial for this category of patients.

Zoledronic acid is a bisphosphonate widely used for prevention of bone‐related complications in osseous metastatic cancer and tumor‐related hypercalcemia \[[15](#onco12957-bib-0015){ref-type="ref"}\], \[[16](#onco12957-bib-0016){ref-type="ref"}\]. Zoledronic acid has shown in different in vitro and animal studies to induce GCTB stromal cell inhibition, apoptosis, and osteogenic differentiation \[[17](#onco12957-bib-0017){ref-type="ref"}\], \[[18](#onco12957-bib-0018){ref-type="ref"}\], \[[19](#onco12957-bib-0019){ref-type="ref"}\], \[[20](#onco12957-bib-0020){ref-type="ref"}\], \[[21](#onco12957-bib-0021){ref-type="ref"}\], \[[22](#onco12957-bib-0022){ref-type="ref"}\]. Further case reports \[[23](#onco12957-bib-0023){ref-type="ref"}\], \[[24](#onco12957-bib-0024){ref-type="ref"}\], \[[25](#onco12957-bib-0025){ref-type="ref"}\], \[[26](#onco12957-bib-0026){ref-type="ref"}\], \[[27](#onco12957-bib-0027){ref-type="ref"}\] and retrospective series support the beneficial use of zoledronic acid and other bisphosphonates as (neo)adjuvant \[[28](#onco12957-bib-0028){ref-type="ref"}\], \[[29](#onco12957-bib-0029){ref-type="ref"}\] or definitive treatment \[[30](#onco12957-bib-0030){ref-type="ref"}\] of GCTB.

We performed a multicenter randomized open‐label phase II trial in patients with high‐risk GCTB. The primary objective was to determine the 2‐year recurrence rate of GCTB after adjuvant zoledronic acid versus standard care. The low accrual and early closure of the trial was due to the clinical introduction of denosumab in the treatment of GCTB. Adjuvant zoledronic acid was feasible, but it did not result in a decrease in 2‐years recurrence rate in this study. For patient, tumor and treatment characteristics, see Table [2](#onco12957-tbl-0002){ref-type="table"}. For relapse free survival, see Figure [1](#onco12957-fig-0001){ref-type="fig"}.

One case of osteonecrosis of the jaw (ONJ) was seen among the eight patients treated in the intervention arm. This patient received three cycles of zoledronic acid, followed by 25 cycles of denosumab treatment when a recurrence was diagnosed, and developed ONJ subsequently. Therefore, the contributing factor of zoledronic acid is not clear. Other zoledronic acid‐related adverse events were grades 1--2. See also the Adverse Events table.

Zoledronate did not decrease the recurrence rate of GCTB in this study. Although this was a randomized study, the (nonsignificant) higher number of recurrences in the zoledronate arm may be explained by more patients with a recurrent GCTB and soft tissue involvement and by more patients who had received suboptimal primary treatment with curettage instead of en bloc resection at primary surgery. All four patients who had a recurrence were treated with curettage, in one case without the use of local adjuvants. Recurrence rates for the high‐risk cases described here are comparable to average recurrence rates in our previously published report \[[13](#onco12957-bib-0013){ref-type="ref"}\]. All recurrences were seen within the first 2 years after surgery, which is comparable to literature \[[8](#onco12957-bib-0008){ref-type="ref"}\], \[[11](#onco12957-bib-0011){ref-type="ref"}\], \[[13](#onco12957-bib-0013){ref-type="ref"}\], \[[14](#onco12957-bib-0014){ref-type="ref"}\], \[[31](#onco12957-bib-0031){ref-type="ref"}\].

Two other prospective trials were performed on the effects of adjuvant treatment with bisphosphonates in GCTB \[[32](#onco12957-bib-0032){ref-type="ref"}\], \[[33](#onco12957-bib-0033){ref-type="ref"}\]. Yu et al. included 16 patients with both primary and recurrent, nonaxial GCTB in a single‐arm prospective trial in which patients received 2 years of adjuvant bisphosphonate treatment (alendronate 10 mg per day for a period of 2 years) after intralesional curettage with PMMA. No recurrences were seen after a median follow‐up of 25 months \[[32](#onco12957-bib-0032){ref-type="ref"}\]. Gouin et al. performed a single‐arm phase II trial among 24 patients with a primary GCTB treated with five adjuvant doses of zoledronic acid (4 mg every 3 weeks) after curettage with either PMMA or bone allograft. Recurrence rate was 15% with recurrences diagnosed 4, 24, and 58 months after surgery \[[33](#onco12957-bib-0033){ref-type="ref"}\].

The benefit of adjuvant zoledronic acid, as well as optimal timing and duration of zoledronic acid treatment, is yet to be determined. The improved mineralization and marginalization \[[28](#onco12957-bib-0028){ref-type="ref"}\], \[[34](#onco12957-bib-0034){ref-type="ref"}\], \[[35](#onco12957-bib-0035){ref-type="ref"}\] leading to easier curettage advocates the use of zoledronic acid in the neoadjuvant setting. In a recent comparative prospective study extended curettage was performed in 37 patients with GCTB with or without three preoperative zoledronic acid infusions (4 mg) at 3‐week intervals. Recurrences were seen in 1 out of 18 patients in the zoledronic acid group and 4 out of 19 patients in the control group (*p* = .47). Curettage tissue showed a decrease in stromal cells and increased calcification in the zoledronic acid group \[[34](#onco12957-bib-0034){ref-type="ref"}\].

Local adjuvant bisphosphonate therapies, such as local zoledronic acid injections or irrigation, and zoledronic acid‐loaded bone cement have been tested in small series \[[36](#onco12957-bib-0036){ref-type="ref"}\], \[[37](#onco12957-bib-0037){ref-type="ref"}\]. Given the rationale of better bioavailability and fewer adverse effects because of lower systemic concentrations, this treatment might prove beneficial in preventing recurrences.

The position of zoledronic acid in the treatment of GCTB next to denosumab is undetermined. Denosumab is a monoclonal antibody that binds the receptor activator of RANK‐ligand, needed to develop and activate osteoclasts. Its use in advanced GCTB has strongly increased over the past few years because of several larger clinical trials that demonstrated tumor growth inhibition and reduced surgical morbidity \[[38](#onco12957-bib-0038){ref-type="ref"}\], \[[39](#onco12957-bib-0039){ref-type="ref"}\], \[[40](#onco12957-bib-0040){ref-type="ref"}\], \[[41](#onco12957-bib-0041){ref-type="ref"}\], \[[42](#onco12957-bib-0042){ref-type="ref"}\]. Despite these positive outcomes, doubts are also raised, first of all regarding the neoadjuvant use of denosumab. Performing a complete curettage becomes more challenging because of the new bone formation and cortical thickening in these lesions after treatment with denosumab \[[43](#onco12957-bib-0043){ref-type="ref"}\]. Further concerns exist in relation to the risk of tumor recurrence after denosumab withdrawal \[[17](#onco12957-bib-0017){ref-type="ref"}\], \[[40](#onco12957-bib-0040){ref-type="ref"}\], \[[44](#onco12957-bib-0044){ref-type="ref"}\]. It is suggested that a complete pathological response cannot be achieved, because denosumab does not have an apoptotic effect on the neoplastic stromal cell population \[[17](#onco12957-bib-0017){ref-type="ref"}\], \[[44](#onco12957-bib-0044){ref-type="ref"}\], \[[45](#onco12957-bib-0045){ref-type="ref"}\], \[[46](#onco12957-bib-0046){ref-type="ref"}\]. The same studies suggested stromal cell inhibition and apoptosis after treatment with zoledronic acid \[[17](#onco12957-bib-0017){ref-type="ref"}\], \[[45](#onco12957-bib-0045){ref-type="ref"}\]; therefore, zoledronic acid might be a more suitable (neo)adjuvant treatment option. A combination of denosumab and bisphosphonate for optimal growth inhibition and apoptosis of the neoplastic cells might be feasible, although safety is an issue here given the overlapping toxicity profile. Larger randomized trials with zoledronic acid and longer follow‐up are needed to give us further insight to the optimal treatment strategy in advanced GCTB, which agents to choose, and the optimal treatment duration.

Figure and Table {#onco12957-sec-3013}
================

![Relapse free survival, Kaplan Meier.](onco12957-fig-0001){#onco12957-fig-0001}

###### Patient, tumor, and treatment characteristics

![](onco12957-tbl-0002){#nlm-graphic-9}

Abbreviations: ---, none; ECOG, Eastern Cooperative Oncology Group; GCTB, giant cell tumor of bone; PMMA, polymethylmethacrylate.

[ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: [NCT00889590](https://www.clinicaltrials.gov/ct2/show/NCT00889590)
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[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).
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[^1]: Periodontal disease: 1 case of suspected osteonecrosis of the jaw, grade 3. This patient received 3 cycles of zoledronic acid followed by 25 cycles of denosumab treatment when a recurrence was diagnosed and developed osteonecrosis of the jaw subsequently.

[^2]: Abbreviation: NC/NA, no change from baseline/no adverse event.
